{"brief_title": "Study of ONTAK (Denileukin Diftitox) in Previously Treated Cutaneous T-Cell Lymphoma Patients", "brief_summary": "The purpose of this study is to provide an opportunity for patients who exhibit progressive disease while receiving placebo on the companion 93-04-11 study to receive ONTAK. It is also designed to determine the effectiveness of ONTAK in Cutaneous T-cell Lymphoma (CTCL) patients whose tumors do not express CD25.", "condition": "Sezary Syndrome", "intervention_type": "Drug", "intervention_name": "ONTAK", "criteria": "Inclusion Criteria: - Patient must have been previously enrolled in Protocol 93-04-11 and randomized to the placebo arm; or the patient met all eligibility criteria for protocol 93-04-11 other than the expression of CD25 on CTCL tumor cells. - CTCL disease Stage Ia - III. - History of less than or equal to 3 previous therapies. Repeated use of the same agent is considered to be 1 therapy unless it is part of a different combination regimen. Only 1 prior combination cytotoxic chemotherapy regimen is permitted. Topical or systemic steroids are not considered a therapy. - Patient must have evaluable or measurable disease. Lymph node involvement no greater than LN2. No CTCL involvement of bone marrow. - No significant pulmonary or cardiac disease. No active CNS, kidney, or liver disease. - No systemic infections. - ECOG performance status of 0 or 1. Exclusion Criteria: \u2022 The 93-04-14 study is no longer open to subjects previously enrolled in 93-04-10 or 92-04-01.", "gender": "All", "minimum_age": "18 Years", "maximum_age": "N/A", "healthy_volunteers": "No", "id": "NCT00051012.xml"}